EN DE
Watch PENTIXAPHARM HOLDING N AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PENTIXAPHARM HOLDING N AG (PTP) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of PENTIXAPHARM HOLDING N AG stock €1.17, price €1.87, that is 37.4% below the price, quality 36 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DE · ISIN DE000A40AEG0

PH PENTIXAPHARM HOLDING N AG logo Thin data Nov 10, 2026

PENTIXAPHARM HOLDING N AG

PTP · XETRA
Very expensive, weak quality

Our calculation puts a fair price 37% below what the stock costs today.

Expensive Growth (revenue 3y +44.2 %/yr in EUR)
Fair value €1.17 · Strongly overvalued
Quality 36/100
Negative free cash flow
Trails peers (1/6)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch PENTIXAPHARM HOLDING N AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€4.60 €1.36 Fair Value €1.17 Oct 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

25‑month range €1.36 – €4.60 · fair‑value band €0.8700 – €1.46 · the €1.87 price screens above the €1.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow PENTIXAPHARM HOLDING N in your weekly email

Every Wednesday you see whether PENTIXAPHARM HOLDING N is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals.

Show moreShow less

The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study.

It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial.

Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.

Stock analysis

PENTIXAPHARM HOLDING N AG (PTP) currently trades at €1.87, while our estimate is €1.17, 37% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €0.8700 (bear) to €1.46 (bull), the price of €1.87 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

PENTIXAPHARM HOLDING N AG reported revenue of €93.0K in FY2025 versus €59.0K in FY2021, a compound +12.0%/yr. Reported net income was −€16.5M in FY2025.

Key figures

Market cap €60.0M Micro · EPS (TTM) €−0.5900 · Return on equity −43.3% · Return on assets (EBIT) −18.2% (5-year average) · Operating margin −23,880% · Revenue (TTM) €242K · Revenue growth (YoY) −91.2% · Free cash flow −€18.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 38% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −37%, PTP screens richer than that median.

Fair Value

Bear €0.8700 Fair Value €1.17 Bull €1.46
Price €1.87 · Downside -37.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 13
How calm the share price moves, does not count
Price momentum 44
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 49
Distance to the 52-week high, does not count
New shares 53
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−21.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,783.1% (2021) → −21,059.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

PTP screens overvalued: fair value 37% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare PENTIXAPHARM HOLDING N AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −37.4% · Below median
Profitability
Return on assets −39.4% · Below median
Growth and dividend
Revenue growth (quarter YoY) −91.2% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.71× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs PTP
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs PTP
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs PTP
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs PTP
argenx SE ARGX $971.55 $908.40 −7% vs PTP
CSL Limited CSL A$201.68 A$181.40 −10% vs PTP
Moderna, Inc MRNA $250.83 $158.70 −37% vs PTP
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs PTP
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs PTP
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs PTP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PENTIXAPHARM HOLDING N AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PENTIXAPHARM HOLDING N AG Fair Value". https://www.fairvalue-calculator.com/stock/PTP

Frequently asked questions

Is PENTIXAPHARM HOLDING N AG (PTP) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is €1.17 versus a price of €1.87, about 37% lower (overvalued).
What is the fair value of PTP?
Our estimate for PENTIXAPHARM HOLDING N AG is €1.17 (as of Nov 10, 2026), built from audited fundamentals. The current price: €1.87.
What is the quality score of PTP?
PENTIXAPHARM HOLDING N AG has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PENTIXAPHARM HOLDING N AG (PTP)?
Our calculated price target is the estimate of €1.17 (as of Nov 10, 2026). Cautious scenario €0.8700, optimistic scenario €1.46. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the PENTIXAPHARM HOLDING N AG stock forecast for 2026?
Our estimate puts fair value at €1.17, about 37% lower versus a price of €1.87 (overvalued). Cautious scenario €0.8700, optimistic scenario €1.46. The calculation is refreshed regularly with new filings.
What is the revenue of PENTIXAPHARM HOLDING N AG (PTP)?
PENTIXAPHARM HOLDING N AG reported trailing-twelve-month revenue of about €242K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of PENTIXAPHARM HOLDING N AG (PTP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PENTIXAPHARM HOLDING N AG it is €1.17 per share (as of Nov 10, 2026), against a price of €1.87.
Is PENTIXAPHARM HOLDING N AG stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PTP trades above its calculated fair value: price €1.87, fair value €1.17, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTP?
No. The price is what the market pays today (€1.87); the fair value is what the company's own numbers justify (€1.17). For PENTIXAPHARM HOLDING N AG the two are €0.7000 per share apart. That gap is exactly why we show both numbers side by side.
How much is PENTIXAPHARM HOLDING N AG worth?
The market values PENTIXAPHARM HOLDING N AG at about €60.0M (market capitalisation, as of Nov 10, 2026). Per share that is €1.87; our models calculate a fair value of €1.17 per share.
What do the bullish and bearish scenarios say about PTP?
Our models span a range for PENTIXAPHARM HOLDING N AG: cautious scenario €0.8700, base €1.17, optimistic €1.46 per share (as of Nov 10, 2026, price €1.87). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PENTIXAPHARM HOLDING N AG (PTP)?
Balance-sheet figures for PENTIXAPHARM HOLDING N AG (as of Nov 10, 2026): return on equity −43.3%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is PTP from its 52-week high?
PENTIXAPHARM HOLDING N AG trades at €1.87, about 34% below its 52-week high of €2.85 and 38% above the low of €1.36 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of €1.17 is for.
Which stocks are comparable to PENTIXAPHARM HOLDING N AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PENTIXAPHARM HOLDING N AG stock attractive at the current price?
The data as of Nov 10, 2026: price €1.87, calculated fair value €1.17 (−37%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. PENTIXAPHARM HOLDING N AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PENTIXAPHARM HOLDING N AG (PTP)?
The closing price on Nov 10, 2026 was €1.87. Our estimate is €1.17, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PENTIXAPHARM HOLDING N AG right now?
The price sits above even our optimistic bull case (€1.46). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of PENTIXAPHARM HOLDING N AG

How large is the market capitalisation of PENTIXAPHARM HOLDING N AG (PTP)?
The market capitalisation of PENTIXAPHARM HOLDING N AG is €60.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of PENTIXAPHARM HOLDING N AG (PTP)?
Earnings per share at PENTIXAPHARM HOLDING N AG are €−0.5900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of PENTIXAPHARM HOLDING N AG (PTP)?
The return on equity (ROE) of PENTIXAPHARM HOLDING N AG is −43.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PENTIXAPHARM HOLDING N AG (PTP)?
On an EBIT basis the return on assets of PENTIXAPHARM HOLDING N AG is −18.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PENTIXAPHARM HOLDING N AG (PTP)?
The operating margin of PENTIXAPHARM HOLDING N AG is −23,880% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PENTIXAPHARM HOLDING N AG (PTP)?
Revenue at PENTIXAPHARM HOLDING N AG is growing −91.2% versus a year earlier (3y avg +44.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does PENTIXAPHARM HOLDING N AG (PTP) generate?
The free cash flow of PENTIXAPHARM HOLDING N AG is −€18.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch PENTIXAPHARM HOLDING N AG in the live analysis

One click puts PENTIXAPHARM HOLDING N AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.